These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8100153)

  • 1. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up.
    Hwang SJ; Chan CY; Lee SD; Wu JC; Tsay SH; Lo KJ
    J Gastroenterol Hepatol; 1993; 8(3):217-23. PubMed ID: 8100153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
    Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M
    Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group.
    Poupon RE; Eschwège E; Poupon R
    J Hepatol; 1990 Jul; 11(1):16-21. PubMed ID: 1975819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid.
    Vuoristo M; Färkkilä M; Karvonen AL; Leino R; Lehtola J; Mäkinen J; Mattila J; Friman C; Seppälä K; Tuominen J
    Gastroenterology; 1995 May; 108(5):1470-8. PubMed ID: 7729640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group.
    Poupon RE; Balkau B; Eschwège E; Poupon R
    N Engl J Med; 1991 May; 324(22):1548-54. PubMed ID: 1674105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bezafibrate for primary biliary cirrhosis.
    Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD009145. PubMed ID: 22259000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis.
    Oka H; Toda G; Ikeda Y; Hashimoto N; Hasumura Y; Kamimura T; Ohta Y; Tsuji T; Hattori N; Namihisa T
    Gastroenterol Jpn; 1990 Dec; 25(6):774-80. PubMed ID: 1980654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary cirrhosis: a 2-year follow-up study.
    Zhu J; Shi Y; Zhou X; Li Z; Huang X; Han Z; Wang J; Wang R; Ding J; Wu K; Han Y; Fan D
    Front Med; 2013 Jun; 7(2):255-63. PubMed ID: 23179137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis.
    Verma A; Jazrawi RP; Ahmed HA; Davis T; Bland JM; Benson M; Orchard RT; Theodossi A; Maxwell JD; Northfield TC
    Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1069-76. PubMed ID: 10524634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study.
    Rolandi E; Franceschini R; Cataldi A; Cicchetti V; Carati L; Barreca T
    Eur J Clin Pharmacol; 1991; 40(5):473-6. PubMed ID: 1679391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis.
    Almasio PL; Floreani A; Chiaramonte M; Provenzano G; Battezzati P; Crosignani A; Podda M; Todros L; Rosina F; Saccoccio G; Manenti F; Ballardini G; Bianchi FP; Scheuer PJ; Davies SE; Craxì A
    Aliment Pharmacol Ther; 2000 Dec; 14(12):1645-52. PubMed ID: 11121914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver.
    Parés A; Caballería L; Rodés J; Bruguera M; Rodrigo L; García-Plaza A; Berenguer J; Rodríguez-Martínez D; Mercader J; Velicia R
    J Hepatol; 2000 Apr; 32(4):561-6. PubMed ID: 10782903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history of pruritus in primary biliary cirrhosis.
    Talwalkar JA; Souto E; Jorgensen RA; Lindor KD
    Clin Gastroenterol Hepatol; 2003 Jul; 1(4):297-302. PubMed ID: 15017671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC.
    Battezzati PM; Podda M; Bianchi FB; Naccarato R; Orlandi F; Surrenti C; Pagliaro L; Manenti F
    J Hepatol; 1993 Mar; 17(3):332-8. PubMed ID: 8315262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    Schattenberg JM; Pares A; Kowdley KV; Heneghan MA; Caldwell S; Pratt D; Bonder A; Hirschfield GM; Levy C; Vierling J; Jones D; Tailleux A; Staels B; Megnien S; Hanf R; Magrez D; Birman P; Luketic V
    J Hepatol; 2021 Jun; 74(6):1344-1354. PubMed ID: 33484775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis.
    Turner IB; Myszor M; Mitchison HC; Bennett MK; Burt AD; James OF
    J Gastroenterol Hepatol; 1994; 9(2):162-8. PubMed ID: 8003650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
    Hirschfield GM; Mason A; Luketic V; Lindor K; Gordon SC; Mayo M; Kowdley KV; Vincent C; Bodhenheimer HC; Parés A; Trauner M; Marschall HU; Adorini L; Sciacca C; Beecher-Jones T; Castelloe E; Böhm O; Shapiro D
    Gastroenterology; 2015 Apr; 148(4):751-61.e8. PubMed ID: 25500425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis.
    Heathcote EJ; Cauch-Dudek K; Walker V; Bailey RJ; Blendis LM; Ghent CN; Michieletti P; Minuk GY; Pappas SC; Scully LJ
    Hepatology; 1994 May; 19(5):1149-56. PubMed ID: 8175136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
    Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
    Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.